ClinicalTrials.gg
CompletedNCT02634801Updated Oct 9, 2019Results posted

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

A Phase 3 interventional study of Fumaric Acid Esters and Methotrexate in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 21 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
11th of 22
162 · median 156
Started
2016
with 2 others
Phase 3
11 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 11th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 10th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Fumaderm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of chronic psoriasis for at least 6 months before baseline.
  • Participants who are candidates for systemic therapy and who are naive to systemic treatment for psoriasis.
  • Have a (PASI score >10 or BSA >10) and DLQI >10 at screening and at baseline.

Exclusion criteria

Exclusion Criteria:

  • Have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.
  • Have received systemic nonbiologic psoriasis therapy.
  • Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis therapy.
  • Have any condition or as addressed in the local labeling for MTX or FAE.
  • Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders or abnormal laboratory values at screening.
  • Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal ulcer.
  • Have had a serious infection or are .
  • At screening, participants with significant, present, or early liver disease, e.g., explained by alcohol consumption or hepatic insufficiency.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24. Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks.

    Drug: Ixekizumab

  • Active comparator
    Fumaric Acid Esters

    Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24. Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.

    Drug: Fumaric Acid Esters · Drug: Ixekizumab

  • Active comparator
    Methotrexate

    7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24. Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.

    Drug: Methotrexate · Drug: Ixekizumab

Interventions

  • DrugFumaric Acid Esters

    Administered orally

  • Administered orally

  • Administered SC

    Also known as: LY2439821

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 24

  2. Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 24

  3. Change From Baseline in PASI Total Score

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). LS mean change from baseline in PASI was calculated using Analysis of Covariance (ANCOVA) with modified Baseline- Observation- Carried Forward (mBOCF) and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  4. Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline

    The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

    Time frame: Week 24

  5. Percentage of Participants Achieving DLQI (0,1)

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant.

    Time frame: Week 24

  6. Change From Baseline on Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant. LS mean change from baseline in DLQI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

    The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score

    The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean change from baseline in PPASI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  9. Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change from baseline in PSSI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  10. Patient Benefit Index (PBI) Overall Benefit Score

    The PBI assessment consists of 2 steps: before treatment, every patient defines his/her treatment needs according to a standardized list (Patient Needs Questionnaire \[PNQ\]). After treatment, the patient rates the degree of benefits achieved (Patient Benefits Questionnaire \[PBQ\]). 25 items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for "did not apply to me" (5) and missing. For each treatment goal the PNQ importance is derived by dividing the respective PNQ item by the sum of all PNQ items. The weighted sum of each PBQ item with its respective PNQ importance yields the PBI score. LS mean was calculated using ANCOVA with LOCF and with a term for treatment.

    Time frame: Week 24

  11. Change From Baseline on Itch Numeric Rating Scale (NRS) Score

    The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  12. Change From Baseline on the Skin Pain Visual Analog Scale (VAS)

    The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  13. Change From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16)

    QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. Whereas 0-5 indicates no symptoms. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  14. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  15. Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  16. Change From Baseline on Patient's Global Assessment (PatGA) of Disease Severity

    The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  17. Change From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score

    PSAB measure is a 3-item scale designed to measure the degree of bothersomeness of skin appearance due to Ps in participants with Ps. Participants are asked to indicate on 3 numeric rating scales (NRS) from 0 (not at all bothered) to 10 (extremely bothered) how bothered they are by any redness or discoloration, thickness, and scaling or flaking on their skin due to Ps. The scores from the 3 NRS items are summed for a total score ranging from 0 to 30, where 0 indicating no bothersomeness and 30 indicating greater bothersomeness. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  18. Change From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score

    NAPPA is a clinical and participant-reported outcomes tool, and consists of 3 components: a questionnaire assessing nail-specific quality of life NAPPA-QoL (Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life), a 2-part questionnaire assessing participant relevant needs and treatment benefits NAPPA-PBI (Nail Assessment in Psoriasis and Psoriatic Arthritis - Patient Benefit Index), and a clinical assessment of objective finger nail psoriasis severity NAPPA-CLIN. Sum of all assessed finger and toes ranging between 0 (no involvement) to 16 (worst involvement). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  19. Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score

    The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a United Kingdom (UK) Population value set to each of the levels in each dimension. This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  20. Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score

    The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The Bolt On PSO is an addition to the EQ-5D-5L that consists of 2 dimensions specific to psoriatic disease: 6) skin irritation (itching) and 7) self-confidence. Index scores for the Bolt On PSO range from 0.0042 to 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  21. Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score

    The EQ-5D 5L is a standardized measure of health status that includes a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health imaginable)- to 100 (best health imaginable)-millimeter (mm) Visual Analog Scale (VAS). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  22. Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  23. Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  24. Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  25. Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score

    The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

    Time frame: Baseline, Week 24

  26. Percentage of Participants With Positive Responses to Neck/Face Psoriasis Question

    Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the participant currently have visible psoriasis on face/neck? (Yes/No) 2. Does the participant currently have psoriasis on the genital area? (Yes/No)

    Time frame: Week 24

  27. Percentage of Participants Positive Responses to Genital Psoriasis Question

    Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the patient currently have visible psoriasis on face/neck? (Yes/No) 2. Does the patient currently have psoriasis on the genital area? (Yes/No) The genital area includes the labia majora (hair-bearing), labia minora modified mucus membrane, and perineum in female patients; and the penis glans, penis - shaft, and scrotum in male patients.

    Time frame: Week 24

  28. Mean Adherence on Medication and Satisfaction With Therapy (STAQ)

    Systemic Therapy Adherence Questionnaire (STAQ) is a 38 item questionnaire that was developed by shortening and adapting the Topical Treatment Adherence Questionnaire (TTAQ) for administration to participants under systemic therapy. The following STAQ items are of special interest for this study. 1. STAQ item 13 (The treatment does not affect my sex life) 2. STAQ item 16 (I am enjoying life again as a result of the treatment) 3. STAQ item 20 (The side effects of the treatment were acceptable) 4. STAQ item 31 (I am satisfied with the efficacy of the treatment) 5. STAQ item 32 (I am satisfied with the tolerability of the treatment) 6. STAQ item 35 (The positive aspects of the treatment outweigh the negative ones). The STAQ items are on a 4-point Likert scale with scores between 0 (strong disagreement) and 3 (strong agreement). LS mean was calculated using ANCOVA with term for treatment.

    Time frame: Week 24

07

Results

Posted Jul 18, 2018

Participant flow

Treatment Period (Weeks 0 to 24), Extension Period (Weeks 24 to 36) followed by post-treatment follow-up period occurring from last treatment visit (week 36), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.

Treatment Period (Weeks 0 to 24)
Participant flow — Treatment Period (Weeks 0 to 24)
MilestoneIxekizumabFumaric Acid EstersMethotrexate
Started545454
Received at least 1 dose of study drug545252
Completed502349
Not completed4315
Withdrew: Adverse event2200
Withdrew: Lack of efficacy020
Withdrew: Lost to follow-up211
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject083
Extension Period (Weeks 24 to 36)
Participant flow — Extension Period (Weeks 24 to 36)
MilestoneIxekizumabFumaric Acid EstersMethotrexate
Started481931
Completed451829
Not completed312
Withdrew: Adverse event001
Withdrew: Lost to follow-up100
Withdrew: Withdrawal by subject111
Withdrew: Missing100
Follow-up Period
Participant flow — Follow-up Period
MilestoneIxekizumabFumaric Acid EstersMethotrexate
Started412646
Completed361838
Not completed588
Withdrew: Lost to follow-up312
Withdrew: Physician decision001
Withdrew: Withdrawal by subject125
Withdrew: Adverse event150

Outcome measures

PrimaryPercentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 2490.722.270.4
Statistical analysis
  • Ixekizumab vs Fumaric Acid Esters · Fisher Exact · p = <.0001 · Risk ratio (rr): 4.08 · 95% CI 2.46 to 6.77
  • Ixekizumab vs Methotrexate · Fisher Exact · p = 0.0137 · Risk ratio (rr): 1.29 · 95% CI 1.06 to 1.56
SecondaryPercentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline79.69.338.9
SecondaryPercentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline40.73.713.0
SecondaryChange From Baseline in PASI Total Score

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). LS mean change from baseline in PASI was calculated using Analysis of Covariance (ANCOVA) with modified Baseline- Observation- Carried Forward (mBOCF) and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in PASI Total Score-16.68 (-18.46 to -14.91)-4.93 (-6.78 to -3.09)-14.61 (-16.42 to -12.80)
SecondaryPercentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline86.513.251.9
SecondaryPercentage of Participants Achieving DLQI (0,1)

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving DLQI (0,1)
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants Achieving DLQI (0,1)63.014.837.0
SecondaryChange From Baseline on Dermatology Life Quality Index (DLQI) Total Score

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant. LS mean change from baseline in DLQI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on Dermatology Life Quality Index (DLQI) Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on Dermatology Life Quality Index (DLQI) Total Score-13.08 (-14.56 to -11.61)-5.37 (-6.88 to -3.86)-12.81 (-14.32 to -11.29)
SecondaryChange From Baseline in Body Surface Area (BSA) Affected by Psoriasis

The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · % Body Surface Affected
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
% Body Surface AffectedIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis-20.64 (-23.21 to -18.08)-5.26 (-7.93 to -2.60)-18.46 (-21.08 to -15.85)
SecondaryChange From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score

The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean change from baseline in PPASI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score-7.23 (-10.88 to -3.59)-2.45 (-6.03 to 1.13)-3.77 (-8.10 to 0.56)
SecondaryChange From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change from baseline in PSSI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score-20.85 (-23.63 to -18.06)-6.76 (-9.58 to -3.94)-18.56 (-21.35 to -15.78)
SecondaryPatient Benefit Index (PBI) Overall Benefit Score

The PBI assessment consists of 2 steps: before treatment, every patient defines his/her treatment needs according to a standardized list (Patient Needs Questionnaire \[PNQ\]). After treatment, the patient rates the degree of benefits achieved (Patient Benefits Questionnaire \[PBQ\]). 25 items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for "did not apply to me" (5) and missing. For each treatment goal the PNQ importance is derived by dividing the respective PNQ item by the sum of all PNQ items. The weighted sum of each PBQ item with its respective PNQ importance yields the PBI score. LS mean was calculated using ANCOVA with LOCF and with a term for treatment.

Time frame:
Week 24
Reported as:
Least squares mean · units on a scale
Patient Benefit Index (PBI) Overall Benefit Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Patient Benefit Index (PBI) Overall Benefit Score3.42 (2.99 to 3.84)2.33 (1.81 to 2.84)2.66 (2.23 to 3.10)
SecondaryChange From Baseline on Itch Numeric Rating Scale (NRS) Score

The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on Itch Numeric Rating Scale (NRS) Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on Itch Numeric Rating Scale (NRS) Score-5.25 (-5.89 to -4.61)-1.50 (-2.15 to -0.84)-4.40 (-5.05 to -3.76)
SecondaryChange From Baseline on the Skin Pain Visual Analog Scale (VAS)

The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline on the Skin Pain Visual Analog Scale (VAS)
Millimeter (mm)IxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Skin Pain Visual Analog Scale (VAS)-33.83 (-39.46 to -28.20)-7.20 (-12.99 to -1.42)-28.29 (-33.98 to -22.60)
SecondaryChange From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16)

QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. Whereas 0-5 indicates no symptoms. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16)
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16)-2.16 (-3.00 to -1.32)-1.01 (-1.89 to -0.14)-2.50 (-3.37 to -1.64)
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)4.45 (2.29 to 6.60)0.57 (-1.64 to 2.77)4.01 (1.83 to 6.19)
SecondaryChange From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores7.13 (4.99 to 9.27)3.39 (1.19 to 5.59)6.99 (4.80 to 9.17)
SecondaryChange From Baseline on Patient's Global Assessment (PatGA) of Disease Severity

The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on Patient's Global Assessment (PatGA) of Disease Severity
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on Patient's Global Assessment (PatGA) of Disease Severity-3.12 (-3.47 to -2.78)-0.87 (-1.23 to -0.51)-2.39 (-2.75 to -2.04)
SecondaryChange From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score

PSAB measure is a 3-item scale designed to measure the degree of bothersomeness of skin appearance due to Ps in participants with Ps. Participants are asked to indicate on 3 numeric rating scales (NRS) from 0 (not at all bothered) to 10 (extremely bothered) how bothered they are by any redness or discoloration, thickness, and scaling or flaking on their skin due to Ps. The scores from the 3 NRS items are summed for a total score ranging from 0 to 30, where 0 indicating no bothersomeness and 30 indicating greater bothersomeness. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score-19.87 (-22.38 to 17.36)-5.18 (-7.82 to -2.54)-15.05 (-17.67 to -12.43)
SecondaryChange From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score

NAPPA is a clinical and participant-reported outcomes tool, and consists of 3 components: a questionnaire assessing nail-specific quality of life NAPPA-QoL (Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life), a 2-part questionnaire assessing participant relevant needs and treatment benefits NAPPA-PBI (Nail Assessment in Psoriasis and Psoriatic Arthritis - Patient Benefit Index), and a clinical assessment of objective finger nail psoriasis severity NAPPA-CLIN. Sum of all assessed finger and toes ranging between 0 (no involvement) to 16 (worst involvement). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score-6.58 (-8.12 to -5.04)-0.14 (-1.91 to 1.62)-3.41 (-5.30 to -1.52)
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score

The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a United Kingdom (UK) Population value set to each of the levels in each dimension. This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score0.15 (0.11 to 0.20)0.04 (-0.01 to 0.09)0.15 (0.10 to 0.20)
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score

The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The Bolt On PSO is an addition to the EQ-5D-5L that consists of 2 dimensions specific to psoriatic disease: 6) skin irritation (itching) and 7) self-confidence. Index scores for the Bolt On PSO range from 0.0042 to 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score0.15 (0.12 to 0.18)0.05 (0.01 to 0.08)0.13 (0.10 to 0.16)
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score

The EQ-5D 5L is a standardized measure of health status that includes a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health imaginable)- to 100 (best health imaginable)-millimeter (mm) Visual Analog Scale (VAS). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score
Millimeter (mm)IxekizumabFumaric Acid EstersMethotrexate
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score16.91 (12.23 to 21.59)6.08 (1.21 to 10.96)13.91 (9.14 to 18.69)
SecondaryChange From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score

The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score3.08 (-3.79 to 9.96)-1.26 (-7.69 to 5.17)0.06 (-5.49 to 5.62)
SecondaryChange From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score

The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score-22.70 (-28.73 to -16.66)-5.29 (-11.10 to 0.52)-20.32 (-25.51 to -15.13)
SecondaryChange From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work

The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work-28.23 (-33.99 to -22.47)-3.45 (-9.38 to 2.47)-23.57 (-29.58 to -17.55)
SecondaryChange From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score

The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score-18.20 (-26.29 to -10.11)-6.20 (-13.66 to 1.27)-19.80 (-26.31 to -13.29)
SecondaryPercentage of Participants With Positive Responses to Neck/Face Psoriasis Question

Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the participant currently have visible psoriasis on face/neck? (Yes/No) 2. Does the participant currently have psoriasis on the genital area? (Yes/No)

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive Responses to Neck/Face Psoriasis Question
Percentage of ParticipantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants With Positive Responses to Neck/Face Psoriasis Question81.826.566.7
SecondaryPercentage of Participants Positive Responses to Genital Psoriasis Question

Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the patient currently have visible psoriasis on face/neck? (Yes/No) 2. Does the patient currently have psoriasis on the genital area? (Yes/No) The genital area includes the labia majora (hair-bearing), labia minora modified mucus membrane, and perineum in female patients; and the penis glans, penis - shaft, and scrotum in male patients.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Positive Responses to Genital Psoriasis Question
Percentage of participantsIxekizumabFumaric Acid EstersMethotrexate
Percentage of Participants Positive Responses to Genital Psoriasis Question85.029.275.0
SecondaryMean Adherence on Medication and Satisfaction With Therapy (STAQ)

Systemic Therapy Adherence Questionnaire (STAQ) is a 38 item questionnaire that was developed by shortening and adapting the Topical Treatment Adherence Questionnaire (TTAQ) for administration to participants under systemic therapy. The following STAQ items are of special interest for this study. 1. STAQ item 13 (The treatment does not affect my sex life) 2. STAQ item 16 (I am enjoying life again as a result of the treatment) 3. STAQ item 20 (The side effects of the treatment were acceptable) 4. STAQ item 31 (I am satisfied with the efficacy of the treatment) 5. STAQ item 32 (I am satisfied with the tolerability of the treatment) 6. STAQ item 35 (The positive aspects of the treatment outweigh the negative ones). The STAQ items are on a 4-point Likert scale with scores between 0 (strong disagreement) and 3 (strong agreement). LS mean was calculated using ANCOVA with term for treatment.

Time frame:
Week 24
Reported as:
Least squares mean · units on a scale
Mean Adherence on Medication and Satisfaction With Therapy (STAQ)
units on a scaleIxekizumabFumaric Acid EstersMethotrexate
STAQ item 132.84 (2.68 to 3.00)2.75 (2.51 to 2.99)2.78 (2.61 to 2.94)
STAQ item 162.82 (2.60 to 3.04)2.00 (1.68 to 2.32)2.43 (2.20 to 2.66)
STAQ item 202.76 (2.51 to 3.01)2.00 (1.66 to 2.34)2.42 (2.17 to 2.66)
STAQ item 312.88 (2.68 to 3.08)2.09 (1.79 to 2.39)2.29 (2.09 to 2.50)
STAQ item 322.86 (2.66 to 3.05)1.95 (1.66 to 2.25)2.50 (2.30 to 2.70)
STAQ item 352.80 (2.58 to 3.02)2.14 (1.82 to 2.46)2.53 (2.31 to 2.75)

Adverse events

Collected over Up to 48 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab-Treatment Period—1/54 (1.9%)37/54 (68.5%)
Fumaric Acid Esters-Treatment Period—3/52 (5.8%)39/52 (75%)
Methotrexate-Treatment Period—1/52 (1.9%)38/52 (73.1%)
Ixekizumab-Extension Period—3/48 (6.3%)24/48 (50%)
Fumaric Acid Esters-Extension Period—1/19 (5.3%)15/19 (78.9%)
Methotrexate-Extension Period—4/31 (12.9%)18/31 (58.1%)
Follow-up Period—4/113 (3.5%)0/113 (0%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventIxekizumab-Treatment PeriodFumaric Acid Esters-Treatment PeriodMethotrexate-Treatment PeriodIxekizumab-Extension PeriodFumaric Acid Esters-Extension PeriodMethotrexate-Extension PeriodFollow-up Period
OsteoarthritisMusculoskeletal and connective tissue disorders0/540/520/520/480/192/310/113
Infected dermal cystInfections and infestations0/540/520/520/481/190/310/113
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/540/520/520/480/191/310/113
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/540/520/520/480/191/310/113
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/541/520/521/480/190/310/113
Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/540/520/521/480/190/310/113
Pancreatic neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/540/520/521/480/190/310/113
Abdominal painGastrointestinal disorders0/540/521/520/480/190/310/113
ColitisGastrointestinal disorders0/541/520/520/480/190/310/113
Gastritis erosiveGastrointestinal disorders0/540/521/520/480/190/310/113
Most frequent other events
Showing 10 of 47
Most frequent other events
EventIxekizumab-Treatment PeriodFumaric Acid Esters-Treatment PeriodMethotrexate-Treatment PeriodIxekizumab-Extension PeriodFumaric Acid Esters-Extension PeriodMethotrexate-Extension PeriodFollow-up Period
DiarrhoeaGastrointestinal disorders1/5424/526/521/481/191/310/113
NasopharyngitisInfections and infestations20/549/5218/5218/486/1910/310/113
Abdominal pain upperGastrointestinal disorders2/5419/526/521/480/190/310/113
FlushingVascular disorders0/5413/520/520/480/190/310/113
Injection site reactionGeneral disorders7/540/520/521/483/196/310/113
HeadacheNervous system disorders7/544/529/521/481/192/310/113
FatigueGeneral disorders4/543/528/520/481/190/310/113
Injection site erythemaGeneral disorders0/540/520/520/482/193/310/113
Injection site swellingGeneral disorders0/540/520/520/482/193/310/113
Tinea pedisInfections and infestations2/540/521/521/482/190/310/113

Baseline characteristics

All randomized participants who had baseline data.

Age, Continuous
Age, Continuous(Years)IxekizumabFumaric Acid EstersMethotrexateTotal
Mean44.3 ± 13.8443.1 ± 14.1638.7 ± 12.9042.1 ± 13.77
Sex: Female, Male
Sex: Female, Male(Participants)IxekizumabFumaric Acid EstersMethotrexateTotal
Female12111841
Male424336121
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IxekizumabFumaric Acid EstersMethotrexateTotal
American Indian or Alaska Native0000
Asian1034
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White434442129
More than one race1010929
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)IxekizumabFumaric Acid EstersMethotrexateTotal
Germany545454162
08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augsburg, 86179, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 10783, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bochum, 44803, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bonn, 53105, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buxtehude, 21614, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Erlangen, 91054, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45122, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 60590, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Friedrichshafen, 88045, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gelsenkirchen, 45883, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20354, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hanau, 63450, Germany
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Kiel, 24105, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lübeck, 23538, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mannheim, 68167, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Münster, 48149, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Selters, 56242, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stuttgart, 70178, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tübingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulm, 89081, Germany
09

References and documents

Publications

  • Reich K, Augustin M, Thaci D, Pinter A, Leutz A, Henneges C, Schneider E, Schacht A, Dossenbach M, Mrowietz U. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2020 Apr;182(4):869-879. doi: 10.1111/bjd.18384. Epub 2019 Nov 19. PubMed 31376153 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2016, 10 months.

Results were first posted in Jul 2018, 1 year 7 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2015
First posted
Dec 18, 2015
StartActual
Jan 20, 2016
Primary completionActual
Nov 29, 2016
CompletionActual
Nov 14, 2017
Results first posted
Jul 18, 2018
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02634801
Responsible party
Sponsor
First posted
Dec 18, 2015
Start date
Jan 20, 2016
Primary completion
Nov 29, 2016
Completion
Nov 14, 2017
Results posted
Jul 18, 2018
Last update
Oct 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion